KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $18.1 billion.

  • Royalty Pharma's Non-Current Assets rose 1018.3% to $18.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $68.2 billion, marking a year-over-year increase of 937.29%. This contributed to the annual value of $18.1 billion for FY2025, which is 1018.3% up from last year.
  • Per Royalty Pharma's latest filing, its Non-Current Assets stood at $18.1 billion for Q4 2025, which was up 1018.3% from $17.5 billion recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Non-Current Assets ranged from a high of $18.1 billion in Q4 2025 and a low of $13.5 billion during Q1 2021
  • Over the past 5 years, Royalty Pharma's median Non-Current Assets value was $14.8 billion (recorded in 2021), while the average stood at $15.2 billion.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 785.08% in 2023, then surged by 1501.48% in 2024.
  • Over the past 5 years, Royalty Pharma's Non-Current Assets (Quarter) stood at $14.6 billion in 2021, then fell by 2.59% to $14.3 billion in 2022, then rose by 5.96% to $15.1 billion in 2023, then rose by 8.69% to $16.4 billion in 2024, then increased by 10.18% to $18.1 billion in 2025.
  • Its last three reported values are $18.1 billion in Q4 2025, $17.5 billion for Q3 2025, and $16.8 billion during Q2 2025.